louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05016921: TcMS to Treat Ventricular Tachycardia
Official title: Transcutaneous Magnetic Stimulation of the Stellate Ganglion to Treat Ventricular Tachycardia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Ventricular Tachycardia
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2021-08-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Open label study of transcutaneous magnetic stimulation targeting the stellate ganglion in patients with ventricular tachycardia


Eligibility criteria: Inclusion Criteria:

* Age \>18years
* Documented ventricular tachycardia within the preceding 72 hours

Exclusion Criteria:

* Pregnancy
* Implanted ventricular assist device
* Metal implanted in heard or neck (except the mouth)
* Implanted medication pumps
* Cochlear implant
* Implanted brain stimulator
* Ocular implant
* History of malignancy in the region of stimulation (neck)

Primary outcomes:
measure: Ventricular Tachycardia
timeFrame: 0-72 hours after enrollment
Secondary outcomes:
measure: Non sustained ventricular tachycardia
timeFrame: 0-72 hours after enrollment
measure: Discomfort
timeFrame: Assessed immediately following stimulation
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
Study officials:
References:
Clinical trial NCT03874221: ARIA to Predict Coronary Artery Disease in HIV-infected Individuals
Official title: Automatic Retinal Image Analysis (ARIA) to Predict Coronary Artery Disease in HIV-infected Individuals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hiv
Coronary Artery Disease
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2019-03-14
Enrollment: 120
Sex: ALL
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All HIV-infected individuals followed up in Metabolic Research Clinic and Infectious Diseases clinic of the Prince of Wales Hospital will be screened for eligibility.

Brief summary: With effective anti-retroviral therapy, non-communicable diseases, such as cardiovascular diseases, have become the major cause of morbidity and mortality for people living with HIV. There is only limited data evaluating the burden and risk factors of cardiovascular disease in the Asian HIV-infected population. Accurate non-invasive tools for prediction of cardiovascular disease, particularly in Asian HIV-infected populations, are urgently needed. Recently, more detailed evaluation of the complex retinal vasculature has been made feasible with advances in digitalized retinal imaging techniques.

This study aims 1. to determine the prevalence of coronary atherosclerosis and obstructive coronary artery disease HIV-infected individuals with one or more cardiovascular disease risk factors in Asia. 2. to determine the performance of automatic retinal image analysis (ARIA) in predicting the risk of coronary artery disease in HIV-infected individuals, as compared to traditional risk prediction tools. Patients will undergo a coronary CT angiogram, followed by an automatic retinal image analysis within 4 weeks post completion of CT angiogram.


Eligibility criteria: Inclusion Criteria:

* Positive anti-HIV antibody
* Age 30 or above
* Presence of one or more risk factors for cardiovascular disease

Exclusion Criteria:

* Presence of overt coronary artery disease
* Impaired renal function
* Allergy to intravenous contrast
* Pregnancy

Primary outcomes:
measure: Coronary atherosclerosis defined as the presence of any plaque in one or more coronary artery segments
timeFrame: 1 year
Secondary outcomes:
measure: Presence of any CAC, Presence of significant CAC, Obstructive coronary artery disease
timeFrame: 1 year
Other outcomes:
Locations:
city: Shatin
country: Hong Kong
facility: Prince of Wales Hospital
Study officials:
affiliation: CUHK
name: Grace Lui
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04441021: Feasibility Assessment of Risk Stratification and Oral Challenge in Hospitalized Children at Low Risk for Antibiotic Allergy
Official title: Feasibility Assessment of Risk Stratification and Oral Challenge in Hospitalized Children at Low Risk for Antibiotic Allergy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Penicillin Allergy
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2020-06-22
Enrollment: 20
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals admitted to Vanderbilt children's hospital admitted to a Pediatric Hospital Medicine service with a penicillin allergy reported in their chart who are medically stable

Brief summary: Children are often reported to have antibiotics allergies, with approximately 10% of the US population labeled as allergic to an antibiotic. Recent studies have demonstrated that a large majority of children with a penicillin allergy label do not have a true IgE-mediated allergy. Appropriately delabeling antibiotic allergies has been shown to improve patient care outcomes and lower health care costs. However, efforts to implement these assessments in practice are lacking, particularly in the hospital setting. Therefore, there is a need for hospital-based risk assessment and delabeling strategies for hospitalized children. The investigator's objective is to determine the feasibility of implementing a hospital-based approach to penicillin allergy risk stratification and evaluation of patients at low-risk for true allergy.


Eligibility criteria: Inclusion Criteria:

* Patients admitted to Vanderbilt children's hospital admitted to a Pediatric Hospital Medicine service with a penicillin allergy reported in their chart who are medically stable

Exclusion Criteria:

* Known pregnancy
* Patients without a primary care provider

Primary outcomes:
measure: Feasibility of Intervention Measure
timeFrame: Within 2 weeks of hospital discharge
Secondary outcomes:
measure: Acceptability of Intervention Measure
timeFrame: Within 2 weeks of hospital discharge
measure: Intervention Appropriateness Measure
timeFrame: Within 2 weeks of hospital discharge
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: James Antoon, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Antoon JW, Grijalva CG, Grisso AG, Stone CA, Johnson J, Stassun J, Norton AE, Kripalani S, Williams DJ. Feasibility of a Centralized, Pharmacy-Led Penicillin Allergy Delabeling Program. Hosp Pediatr. 2022 Jul 1;12(7):e230-e237. doi: 10.1542/hpeds.2021-006369.
Clinical trial NCT01677221: Effects of Acleara Needle Insert on Acne
Official title: A Clinical Trial Investigating the Effects of Acleara Needle Insert on Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acne Vulgaris
Keywords: acne
inflammatory acne
intense pulsed light
Lead sponsor: Theravant Corporation
Sponsor class: INDUSTRY
First posted: 2012-08-31
Enrollment: 30
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This prospective, open-label study will be conducted in 15 healthy subjects per clinical site ages 14 or older who meet the inclusion/exclusion criteria. Each subject may have up to 5 lesions treated on the face, chest or back with the Acleara insert. Subjects will receive up to 3 follow up visits and evaluated for improvement in acne lesions and monitored for any adverse events.


Eligibility criteria: Inclusion Criteria:

* Subjects \>14 years of age
* Subject has mild to moderate acne vulgaris on the face, chest or back.
* Subject has one or more inflammatory acne lesions on face, chest or back.
* Willingness to participate in the study
* Informed consent agreement signed by the subject
* Willingness to follow the treatment schedule and post treatment care requirements
* Willingness to remain on current acne therapy as directed by the Investigator.

Exclusion Criteria:

* Subject has an infection or other dermatologic condition (aside from acne) in the area to be treated
* Subject is immunosuppressed
* Subject is unable to comply with treatment or follow-up visits
* Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Primary outcomes:
measure: Subject assessment of reduction in acne lesion size
timeFrame: 24-72 hours, 1-2 weeks, 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: White Plains
country: United States
facility: Charles County Dermatology Associates
state: Maryland
city: Bellaire
country: United States
facility: Bellaire Dermatology Associates
state: Texas
Study officials:
References:
Clinical trial NCT02156921: App-guided Training in eFAST Ultrasound
Official title: Cost-effectiveness of Mobile App-guided Training in Extended Focused Assessment With Sonography for Trauma (eFAST): A Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Learning Outcome
Training Efficiency
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Copenhagen Academy for Medical Education and Simulation
name: University of Copenhagen
First posted: 2014-06-05
Enrollment: 34
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study aims to investigate the cost-effectiveness of app-based self-directed ultrasound training compared to self-directed training with written handouts on subsequent performance on simulated patient cases and theoretical cases.


Eligibility criteria: Inclusion Criteria:

* First year medical doctor
* Provided written informed consent

Exclusion Criteria:

* Prior practical ultrasonography experience such as performing independent ultrasonography scans, or participation in any post-graduate ultrasonography courses.

Primary outcomes:
measure: Video recording of ultrasound skills, rated by consultant radiologists.
timeFrame: Ratings are to be completed within three months of performance.
measure: Cost-effectiveness of mobile app guided versus textbook guided training
timeFrame: September 2016
Secondary outcomes:
measure: Diagnostic accuracy
timeFrame: On site via checklist, evaluated on average one day after performance.
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Copenhagen Academy for Medical Education and Simulation
state: Capital Region
Study officials:
affiliation: Copenhagen Academy Of Medical Education And Simulation
name: Philip M Nilsson
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03385421: Nutritional Practices and Outcomes in Non-Invasive Ventilation
Official title: Nutritional Practices and Outcomes in Non-Invasive Ventilation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Invasive Ventilation
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
First posted: 2017-12-28
Enrollment: 400
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population admitted to PICU in whom NIV was initiated

Brief summary: The Nutritional Practices and Outcomes in Non-Invasive Ventilation (NPO/NIV) study is a collaboration with lead sites from pediatric critical care units within US and Canada, and participating sites from multiple international regions. The goal of NPO/NIV is to understand how non-invasive ventilation (NIV) is used to treat critically ill children and, concurrently, how these children are fed while on NIV. Designed as a period prevalence study, NPO/NIV will collect observational, cross-sectional data over the course of five study weeks. Each study week will require two days of screening for eligible patients. On Mondays, study staff will screen for patients eligible in the previous 48 hours. On Tuesdays, study staff will screen for patients eligible in the previous 24 hours. Patients meeting study inclusion will be eligible to complete V0, V1, and V2. Included patients will be followed for 7 days after the initiation of NIV or until the patient is discharged from the pediatric intensive care unit. This study was granted exempt status by the University of Arizona Human Subjects Protection Program, including a waiver of informed consent. As no personal health information is transmitted during the course of the study, the University of Arizona does not require Data Use Agreements between sites to participate.


Eligibility criteria: Inclusion Criteria:

* Patient admitted to the Pediatric ICU
* in whom noninvasive ventilation (NIV) was initiated within previous 48 hours (NIV use includes any High Flow Nasal Canula \> 2 lpm flow , continuous positive airway pressure or bilevel pressure or neurally adjusted ventilatory assist)

Exclusion Criteria:

Patients with:

* chronic home NIV use for \>12 hours per day
* limitations of care decisions made
* Cardiac surgery during this admission
* Acute gastro intestinal bleeds
* Abdominal surgery in previous 48 hours
* Gut graft versus host disease
* Chronic parenteral nutrition
* Short Gut Syndrome

Primary outcomes:
measure: hospital mortality
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: Grenoble
country: France
facility: CHU Grenoble-Alpes
Study officials:
affiliation: University of Arizona
name: Katri Typpo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02160964: Using a Novel Algorithm to Improve the Retrieval Rate of Inferior Vena Cava Filters (iRetrieve Study)
Official title: A Prospective Multi-center Study Using a Novel Algorithm to Improve the Retrieval Rate of Inferior Vena Cava Filters Placed Across the US
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Venous Thromboembolism,
Pulmonary Embolism,
Deep Vein Thrombosis,
Keywords: Inferior Vena Cava
Lead sponsor: Heart and Vascular Outcomes Research Institute
Sponsor class: OTHER
First posted: 2014-06-11
Enrollment: 1786
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participating study centers will enroll patients and enter data in the web-based platform that include demographics, clinical features, and clinical pathway

Brief summary: Since 2003, that the first retrievable IVC filter was introduced in the U.S,improvements have been made in the filter design to resolve problems of structural integrity and increase the ability to remove the filter after longer periods of time.The FDA issued a communication in August 2010 advising physicians to remove retrievable filters whenever possible and updated that letter again in May 2014 due to concerns that these retrievable IVC filters, intended for short-term placement, are not always removed once a patient's risk for PE subsides. Known long term risks associated with IVC filters include but are not limited to lower limb deep vein thrombosis (DVT), filter fracture, filter migration, filter embolization and IVC perforation.

Detailed description: Several studies have shown that approximately 80% to 85% of optional IVC filters are never retrieved. The successful removal of retrievable filters requires diligent patient follow-up and interdepartmental cooperation, and even so, successful removal is not always possible. American College of Chest Physicians (ACCP) guidelines for IVCF placement indications advocates a close, structured follow-up of retrievable IVCFs to improve filter retrieval rates.

Using a retrieval algorithm and pathway program, a score will trigger a secure email and text messages sent to both physician and patient at different timelines, for follow up so as to retrieve filter placed.

Eligibility criteria: Inclusion Criteria:

* Data obtained in line with good clinical practice, applicable laws and regulation

Exclusion Criteria:

-

Primary outcomes:
measure: Filter retrieval rate
timeFrame: 24 Months
Secondary outcomes:
measure: Absence of major adverse event
timeFrame: 24 Months
Other outcomes:
Locations:
Study officials:
affiliation: Heart and Vascular Outcomes Research Institute
name: Uchenna Onyeachom
role: STUDY_DIRECTOR
affiliation: University Of Michigan Health System, Ann Arbor
name: John Rectenwald, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05750264: Intravenous Ibuprofen Postoperative Analgesia After Abdominal Hysterectomy
Official title: Efficacy of Intravenous Ibuprofen in Multimodal Pain Management After Open Abdominal Hysterectomy: A Randomised Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Post Operative Analgesia
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2023-03-01
Enrollment: 152
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The current research is designed to investigate the analgesic efficacy of intravenous ibuprofen on the postoperative analgesic requirements, pain intensity and other recovery parameters.

Detailed description: The patients will be given general anaesthesia. Anaesthesia will be induced by propofol 1-2 mg/kg, and fentanyl 1-2 µg/kg. Endotracheal intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane in oxygen - air mixture. Transversus abdominis plane block will be performed at the end of the operation. A postoperative analgesic regimen according to group allocation will be started.

Eligibility criteria: Inclusion Criteria:

* American Society of anaesthesiologists physical status I to III.
* Open abdominal hysterectomy operations

Exclusion Criteria:

* History of gastrointestinal bleeding.
* History of intracranial haemorrhage.
* Pregnancy and lactation.
* Taking angiotensin converting enzyme(ACE) inhibitors or anticoagulation drugs.
* Asthmatic, hepatic,renal or heart failure.
* Abnormal platelet count.

Primary outcomes:
measure: Morphine consumption
timeFrame: Postoperative up to 24 hours
Secondary outcomes:
measure: Pain intensity
timeFrame: Postoperative up to 24 hours
measure: Anaesthesia recovery time
timeFrame: Perioperative
measure: Duration of post anaesthesia care unit stay
timeFrame: First postoperative 24 hours
measure: Time of first ambulation
timeFrame: First postoperative 24 hours
measure: Duration of hospital stay
timeFrame: Postoperative up to 4 weeks
measure: Heart rate
timeFrame: Perioperative
measure: Mean arterial blood pressure
timeFrame: Perioperative
measure: Arterial oxygen saturation
timeFrame: Perioperative
measure: End tidal carbon dioxide
timeFrame: Perioperative
measure: Respiratory rate
timeFrame: Perioperative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Medicine
state: Shebin Elkom
Study officials:
affiliation: Menoufia University
name: Abd-Elazeem A Elbakry, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Menoufia University
name: Amal G Safan, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Menoufia University
name: Sadik A Sadik, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06033664: Grocery Prescription Program for Medicaid Adults With Hypertension or Type 2 Diabetes
Official title: Grocery Prescription Program for Medicaid Adults With Hypertension or Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes Mellitus
Hypertension
Keywords: Food Insecurity
Food as Medicine
Medicaid Adults
Lead sponsor: University of Kentucky
Sponsor class: OTHER
Collaborators: name: Instacart Health
name: Kentucky Association of Health Plans
First posted: 2023-09-13
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate the effectiveness of a grocery prescription program in adults diagnosed with either Type 2 Diabetes Mellitus or Hypertension. Participants will enroll in Instacart Fresh Funds program. Once enrolled each week participants will select foods that are eligible in the Fresh Funds Program to be delivered to their home for 12 weeks. Participants will also participate in a survey at the beginning of the study and at the end of the study.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Type 2 Diabetes Mellitus, hemoglobin A1c = 7.0% and = 12.0% in last 12 months, or diagnosis of hypertension
* Experiencing food insecurity as indicated by 2-item Hunger Vital Sign
* English speaking
* No plans to move from the area for at least 1 year
* Willing and able to accept text messages
* Free living to the extent that participant has control over dietary intake
* Willing and able to provide written informed consent and participate in all study activities.

Exclusion Criteria:

* Participant in diabetes, nutrition, or weight research intervention in last 12 months
* Another member of the household is already enrolled in this study
* Considering bariatric surgery in the next year or prior bariatric surgery
* Lack of safe, stable residence and ability to store meals

Primary outcomes:
measure: Number of participants with a percentage change in Hemoglobin A1C (HbgA1C)
timeFrame: baseline and post intervention, approximately 12 weeks
Secondary outcomes:
measure: Change in blood pressure
timeFrame: baseline and post intervention, approximately 12 weeks
measure: Change in food insecurity
timeFrame: baseline and post intervention, approximately 12 weeks
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Alison Gustafson, PhD
role: PRINCIPAL_INVESTIGATOR
References: